#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Head and neck cancer Adenomatous polyposis coli Hypophosphatasia Cholangiosarcoma Amyotrophic lateral sclerosis Congenital generalised lipodystrophy Arterial tortuosity syndrome Uveal melanoma Congenital cystic kidney disease Hereditary optic atrophy Malignant melanoma Dermatomyositis Laryngeal squamous cell carcinoma Bulbospinal muscular atrophy congenital Small for dates baby More trials…

    Learn about Rare Diseases

    Hepatic angiosarcoma Hepatic angiosarcoma – Basic Information Hepatic angiosarcoma – Treatment Synovial sarcoma recurrent Alagille syndrome – Treatment Familial amyotrophic lateral sclerosis – Basic Information MELAS syndrome – Treatment Brain stem glioma – Treatment Mucopolysaccharidosis I – Treatment Pituitary-dependent Cushing’s syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Gindameran Hhalpc Etidronate Disodium Cat Epithelia Frexalimab Interferon Gamma Sar-443579 SAR443820 Keto-Isoleucine Calcium Basimglurant Bi 1291583 Immunostimulants Oteracil Leuprorelin Acetate Aluminium 99MTC-EUK-(SO3)CY5-MAS3 Recombinant Interferon Beta-1B Ciltacabtagene Autoleucel Ergocalciferol Bp SONLICROMANOL HYDROCHLORIDE More therapies…

    Learn about Your Condition

    Obstructive pancreatitis Dyspnoea Cutaneous sarcoidosis Invasive breast carcinoma SAPHO syndrome Chronic kidney disease Rhinitis allergic Tachypnoea Renal injury Metabolic disorder Delirium Vomiting Head and neck cancer Urea cycle disorder Meningococcal infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Krankenhaus Nordwest GmbH

Krankenhaus Nordwest GmbH

Steinbacher Hohl 2-26, Praunheim, Frankfurt, 60488, Germany

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Durvalumab and Tremelimumab for Patients with Advanced Liver Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Tremelimumab
    • Durvalumab
    • Infliximab
    France Germany Italy Spain

  • Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Human Igg1 Kappa Monoclonal Antibody Against Tigit
    • Dostarlimab
    • Pembrolizumab
    Belgium Bulgaria Croatia Czechia Estonia Finland +14

  • Study on Pelareorep and Atezolizumab for Patients with Advanced or Metastatic Gastrointestinal Cancers

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Pelareorep
    • Atezolizumab
    Germany

  • Study of Pembrolizumab, Trastuzumab, and Drug Combination for Patients with HER2-Positive, Localized Esophagogastric Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Disodium Folinate
    • Docetaxel
    • Fluorouracil
    Germany

  • Study of MCLA-129 with Chemotherapy and Osimertinib for Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Mcla-129
    • Carboplatin
    • Docetaxel
    Belgium France Germany Italy The Netherlands Spain

  • Study on Brigatinib, Ceritinib, and Alectinib for Patients with Advanced ALK+ Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Alectinib
    • Crizotinib
    • Ceritinib
    Germany

  • Study Comparing ONC-392 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After PD-1/PD-L1 Inhibitor Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Humanised Igg1 Monoclonal Antibody Against Cd152
    • Docetaxel
    Belgium Germany Italy The Netherlands Spain

  • Study of Pembrolizumab and Lenvatinib for Patients with Advanced Liver Cancer Resistant to Previous Immunotherapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hepatic cancer
    Investigated Drugs:
    • Lenvatinib
    • Pembrolizumab
    Germany

  • Study of Tiragolumab and Atezolizumab for Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Atezolizumab
    • Tiragolumab
    Austria Germany Greece Hungary Italy The Netherlands +2

  • Study of Zanidatamab and Tislelizumab Combined with Chemotherapy for Patients with Advanced or Metastatic HER2-positive Gastroesophageal Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Oesophageal adenocarcinoma
    • Gastric cancer
    Investigated Drugs:
    • Loperamide
    • Zanidatamab
    • Capecitabine
    Belgium Estonia France Germany Greece Ireland +6
Previous Page
1 … 12 13 14

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!